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Globally and in Africa specifically, female sex workers (FSWs) are at an extraordinarily high risk of contracting human immuno-
deficiency virus (HIV). Pre-exposure prophylaxis (PrEP) has emerged as an effective and ethical method with which to prevent 
HIV infection among FSWs. PrEP efficacy is, however, closely linked to adherence, and adherence to PrEP among FSWs is a com-
plex and interrelated process that has been shown to be of importance to public health policies and HIV control and intervention 
programs. This comprehensive review categorizes barriers to and facilitators of adherence to HIV PrEP for FSWs, and describes five 
strategies for promoting PrEP adherence among FSWs. These strategies encompass 1) a long-term educational effort to decrease 
the stigma associated with sex work and PrEP use, 2) education on how PrEP works, 3) lifestyle modification, 4) research on next-
generation PrEP products to address the inconvenience of taking daily pills, and 5) integration of PrEP into existing services, such 
as social services and routine primary care visits, to reduce the economic burden of seeking the medication. Our review is expected 
to be useful for the design of future PrEP intervention programs. Multidisciplinary intervention should be considered to promote 
PrEP adherence among FSWs in order to help control the HIV epidemic.
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INTRODUCTION
Human immunodeficiency virus infection and acquired im-
mune deficiency syndrome (HIV/AIDS) continue to be a ma-
jor global public health issue.1 By the end of 2018, an estimat-
ed 37.9 million individuals worldwide were living with HIV/
AIDS.2,3 However, not all population sub-categories face the 
same risk of acquiring HIV/AIDS. Globally and in Africa spe-
cifically, female sex workers (FSWs) are at an extraordinarily 
high risk of contracting HIV4 due to a complex intersection of 
multiple social, cultural, and economic factors: sex workers are 
defined as workers who provide and/or are engaged in sexual 
activities or acts in exchange for monetary, materialistic, or any 
type of support, favors, or gain.5,6 An estimated 29.3% of FSWs 
were living with HIV/AIDS in sub-Saharan Africa in 2014.7 Mean-
while, research has indicated that sex workers and clients of sex 
workers and other sexual partners account for 3% and 19% of 
new yearly HIV infections, respectively.2 
Globally, different approaches and public health efforts have 
been proposed and implemented to reduce HIV incidence 
rate. Traditionally, barrier methods, such as condom use, have 
been at the center of HIV protection efforts and have only prov-
en partially efficient.8-10 Recently, newer protection methods 
have been developed, such as bio-medical, anti-retroviral, pre-
exposure prophylaxis (PrEP). However, even with these newer 
approaches, the HIV/AIDS epidemic remains partially uncon-
trolled. In 2018, 1.7 million people globally became newly in-
fected with HIV, an average of 5000 infections per day.2,3 Fig. 1 
illustrates the 27-year global trend of new HIV infections, AIDS-
related deaths, and people living with HIV.2 Even though the 
number of people living with HIV and HIV mortality are on the 
decline, they are far from null, and the number of HIV/AIDS in-
fections are on the rise. 
Studies of HIV/AIDS prevention programs have specifically 
targeted FSWs,8 for whom different approaches and interven-
tions have been described and reported. Unlike counseling to 
promote condom use and conditional cash transfer for safer 
sex, PrEP has emerged as a more effective and ethical alterna-
tive option for HIV/AIDS prevention among FSWs. Designed 
for use as a preventative and prophylactic intervention, oral 
PrEP comprises the use of antiretroviral drugs prior to HIV ex-
posure of healthy subjects in order to minimize and block HIV 
transmission and subsequent infection with the virus.11 Multi-
ple studies have demonstrated that PrEP is highly effective 
with appropriate subject compliance and that the protective 
effect appears to be long-lasting.12 The Centers for Disease Con-
trol and Prevention (CDC) announced that daily PrEP reduces 
the risk of contracting HIV from sex by more than 90%, despite 
it being less effective and protective when taken inconsistently 
or erratically.13 Thus, adherence to taking PrEP as prescribed 
has become an element of extreme importance.
Although the use of and adherence to PrEP have already prov-
en to be effective in preventing HIV infection among FSWs, few 
studies have looked at the use of PrEP among FSWs. Therefore, 
our comprehensive review focused on the barriers to and fa-
cilitators of adherence to HIV PrEP among FSWs. This review 
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Fig. 1. Global number of AIDS-related deaths, new HIV infections, and people living with HIV (1990–2017). HIV, human immunodeficiency virus; AIDS, 
acquired immune deficiency syndrome. Data used in this Figure from https://www.unaids.org/en/resources/fact-sheet.
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also suggests a roadmap for future PrEP intervention programs 
targeting this underserved and vulnerable sub-population.
 
DEFINITIONS AND SCOPE OF THE REVIEW
Adherence is defined as the extent to which a person’s behav-
ior (e.g., taking medication, following a diet, and/or changing 
lifestyle) corresponds with agreed recommendations from a 
health worker.6 Use of antiretroviral drugs in our study refers to 
the use of medication for the prevention of HIV infection and 
includes drugs for preventing mother-to-child transmission, 
drugs to reduce the transmission among sero-discordant sex-
ual partners, and drugs to prevent the acquisition of HIV after 
exposure. PrEP for HIV refers to the use of antiretroviral drugs 
by people who are HIV negative before coming into contact 
with HIV to reduce the risk of infection. Post-exposure prophy-
laxis (PEP) for HIV comprises the use of antiretroviral drugs 
among people who are HIV negative and came into contact 
with HIV (within the past 72 hours).11
Studies presenting quantitative data on PrEP for FSWs were 
reviewed, and those with strategies for PrEP adherence were 
included in this review. A comprehensive review was carried 
out for all 11 articles of interest. Findings and discussions on 
adherence to PrEP among FSWs were classified into different 
categories: social values and stigma, education on PrEP, life-
style (substance use and coitus), inconvenience, and econom-
ic burden. The characteristics of the 11 studies used in our re-
view are summarized in Table 1. 
 
HIV PRE-EXPOSURE PROPHYLAXIS
In July 2012, the Food and Drug Administration approved the 
combination of emtricitabine and tenofovir disoproxil fuma-
rate as a PrEP formulation for HIV protection in both men and 
women.14,15 Since then, PrEP has been proven to be a highly 
plausible HIV preventive method, with strong evidence-based 
data on its safety and effectiveness.16 
Pharmacokinetic studies suggest that adherence interven-
tions are particularly important and impactful for women and 
should be carefully designed and implemented. Even though 
PrEP provides flexibility with regards to its method of admin-
istration [oral or topical (vaginal/rectal gel)], its use is subject 
to heterogeneity, as shown in our results. PrEP clinical trials 
have also revealed mixed efficacy results: BostwanaTDF2,17 
PartnersPrEP,18 and CAPRISA19 reported efficacy of up to 72%. 
The VOICE20 and FEMPrEP21 trials were cut short over subop-
timal efficacy concerns.4 In most of these trials, PrEP efficacy 
was strongly related to adherence to this bio-medical interven-
tion, with evidence of non-efficaciousness corresponding with 
poor adherence and high efficacy with better adherence.17,22,23 
Adherence to PrEP has been shown to be of extreme volatility 
and unpredictability, secondary to many FSWs’ personal, ex-
ternal, and environmental factors and circumstances. 
Adherence to PrEP has been quantified objectively in mul-
tiple studies. The drug is most effective when it reaches maxi-
mum intracellular concentration. However, its time window is 
highly variable and tissue-specific, ranging between 1 week 
for rectal tissue penetration and up to 20 days for serum and 
cervico-vaginal penetration.24 Subsequently, pharmacokinetic 
studies have suggested that protection of the cervico-vaginal 
organs against HIV requires a minimum of 85% adherence, 
corresponding to at least seven doses per week. Similarly, for 
colo-rectal organ protection, adherence should be in the range 
of 28%, corresponding to two to seven doses per week.25
PRE-EXPOUSRE PROPHYLAXIS AND 
FEMALE SEX WORKERS
Within different communities across a wide geographical 
distribution, PrEP has been shown to be an effective and sus-
tainable option for HIV/AIDS prevention intervention among 
FSWs.26 The success of PrEP intervention, however, is heavily 
dependent on the user’s willingness and compliance with the 
prescribed PrEP regimen, and a lack of awareness and insuffi-
cient knowledge regarding this technique by both healthcare 
providers and patients/subjects are major barriers to its opti-
mal benefit. In order to ensure its ultimate effect in controlling 
the spread of the virus, adherence to the prescribed regimen is 
of utmost importance. Indeed, all clinical trials have conclud-
ed that PrEP efficacy is contingent upon regimen adherence.27 
However, FSWs often find themselves in an underserved con-
text of poverty, lacking significant opportunities for education 
or adequate healthcare.28,29 Moreover, they often face misogy-
nist and gender-based obstacles, along with financial, soci-
etal, and cultural barriers,29,30 that limit large-scale implemen-
tation and efficient HIV/AIDS control among FSWs using the 
PrEP method.30 
PrEP has been described as an empowering approach with 
which to ensure self-protection and health wellbeing among 
FSWs.31 This method allows FSWs to use PrEP without the need 
for consent or approval from their clients and partners. Howev-
er, overcoming the challenges and barriers to adherence when 
implementing a PrEP intervention requires enormous effort 
and a multidisciplinary road map and actions from variable 
stakeholders.32 
FACTORS AFFECTING THE ADHERENCE 
TO PRE-EXPOUSRE PROPHYLAXIS
A representative study on the feasibility of implementing PrEP 
interventions among FSWs in South India33 revealed major 
obstacles for adherence thereto. In the study, challenges to tak-
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ing PrEP every day were surveyed among 424 FSWs. The top 
five reasons were fear of possible side effects (61.8%), social stig-
ma secondary to PrEP use (47.2%), client or partner not giving 
permission or approval for PrEP use (39.4%), fear of being sus-
pected/judged of carrying HIV (37.5%), and difficulties with 
daily tablet intake (33.0%): study participants were asked to 
choose all that applied. In addition to this report, in an attempt 
to identify factors affecting adherence to PrEP, we comprehen-
sively reviewed the literature, and the results are summarized 
in Table 1.
Social values and stigma
Studies have pointed out the influence of social factors on 
PrEP adherence among FSWs. A study in Kenya found that at-
titudes among sex workers towards the use of PrEP were tied 
to positive personal and social values.34 A study of at-risk pop-
ulations in Kenya highlighted a number of barriers and facili-
tators to PrEP regimens, including concerns around stigma 
and discrimination.35
Focus groups on experiences with PrEP among men who 
have sex with men (MSM) and FSWs in Kenya found that al-
though the acceptance of oral PrEP was high, concerns around 
the social costs of PrEP (e.g., stigma, gossip, rumors) were per-
vasive.4 Relationship factors were also associated with improved 
adherence to PrEP and, thus, greater effectiveness.34,36 
A study on Nairobi-based FSWs reported that perceived stig-
ma from other FSWs based on the notion that a person using 
PrEP is likely to be HIV-positive also emerged as one of the bar-
riers to seeking PrEP,37 which is highly likely to be related to low-
er adherence. Similarly, one PEP reported fear of stigmatization 
from healthcare providers, especially upon repeated PEP re-
quests, as a pertinent issue, since it would possibly imply that 
the FSW was not taking any measures to avoid the circumstanc-
es that led to previous PEP requests.37 
Lack of education
In a study on FSWs in Baltimore, South Africa, PrEP education 
was suggested as one potential means through which to in-
crease adherence to PrEP.38 Some sex workers were willing to 
use PrEP if it had limited side effects and could be used intermit-
tently, suggesting the need to include PrEP education on known 
and unknown side effects, careful messaging about side ef-
fects, guidance on intermittent use, and proper counseling on 
medication adherence and management for those initiating 
PrEP.38
Regarding education, research has indicated that one effec-
tive strategy is to focus on PrEP within existing curricula, cam-
paigns, and interventions for antiviral therapy and PEP, while 
framing it as another modality of contraception/ prevention.39 
Awareness and understanding were important themes when 
exploring PrEP acceptability. PrEP motivations included the 
availability of choice, taking into account PrEP challenges and 
barriers; and, de-stigmatizing and empowering PrEP deliv-
ery.39 Participant discussions and proposal also highlighted 
the central role of developing clear education and messaging 
to precisely convey the concept of PrEP and intervention inte-
gration into supportive and individulaized services.4
In a study on FSWs in South Africa, the importance of adher-
ence was emphasized after 1 month of initiation of PrEP dur-
ing 1-month check-ins;40 however, the authors did not evalu-
ate whether it was associated with higher adherence. FSWs 
who initiated PrEP were scheduled for an initial 1-month fol-
low-up to assess safety and/or adherence issues, after which 
they were scheduled for quarterly clinical testing and safety 
monitoring visits.40 The importance of consistent and high ad-
herence was emphasized for PrEP use; however, because par-
ticipants could cycle on and off medication during periods of 
lower risk as desired and remain in the study,40 there were no 
data on women who did not return to the study. Another short-
coming of this study was that adherence and sexual behavior 
data were self-reported, increasing the possibility of recall and 
social desirability biases.40 
In a study on PrEP and early HIV treatment interventions 
for FSWs in South Africa, messaging and education were em-
phasized to promote adherence.41 The authors of the study 
mentioned that it is important to focus on strategies for and the 
philosophy around supporting PrEP adherence and condom 
use, both in early messaging and in on-going education and 
monitoring for sex workers.41
LIFESTYLE MODIFICATION
Complexities of daily life pose challenges to PrEP adherence.35 
A study that examined vaginal washing and vaginal lubrica-
tion among FSWs in Tijuana and Ciudad Juarez, Mexico docu-
mented moderate (39%) and high (54%) prevalences of vaginal 
washing and lubrication in the past month, respectively, suggest-
ing that vaginal PrEP products formulated as douches or gels 
may be acceptable HIV prevention methods to many FSWs in 
the Mexico-US border region.42 The authors of the study also 
identified several predictors of each vaginal practice, providing 
insight into the characteristics of FSWs for whom these vaginal 
PrEP products may be most acceptable.42 
Lifestyle factors, such as substance use, can affect PrEP ad-
herence. One study found that combined use of illicit drugs 
and tenofovir disoproxil fumarate can be nephrotoxic. Thus, 
guidelines call for quarterly visits that should include HIV test-
ing, STI assessment, adherence counseling, and risk reduction 
counseling.43 In an at risk-population in Kenya, researchers 
noted that substance use was a barrier to adherence: alcohol 
use was a reason for not taking pills on time or not taking them 
altogether.35 In the same study, the authors identified the fre-
quency of sex as another lifestyle issue that affected lower PrEP 
adherence. Intermittent dosing, especially after sexual coitus, 
may not be appropriate for populations at-risk with relatively 
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high rates of transactional sex work. Travel was also mentioned 
as one lifestyle factor that interfered with proper medication in-
take.40 Another study on African MSMs and FSWs reported that 
adherence to any post-coital doses was 26%.44
Inconvenience 
When using PrEP, tablets should be taken daily, posing incon-
venience for the user. A study among FSWs in India reported 
that 40 survey participants (33%) expressed daily intake as a 
challenge to PrEP use and pointed to frequent travel and un-
predictable work schedules as obstacles towards adherence.32 
A study among FSWs in the Mexico-US border region report-
ed that the study participants preferred monthly product use to 
daily and on-demand use, with which they may have perceived 
as less burdensome and easier to comply.42 
Economic burden
Research has indicated that the extreme poverty and material 
insecurity that typically drives sex work in sub-Saharan Africa 
may render HIV prevention and PrEP adherence a lower pri-
ority than meeting basic needs (e.g., food, shelter) for many 
women.4 Although 80% of surveyed South Indian FSWs indi-
cated that they would be willing to pay for PrEP, it was also clear 
that adherence might be a challenge if women were expected 
to assume the cost of medication.34 However, considering that 
most FSWs live in poverty, it is likely that imposing an eco-
nomic burden would negatively impact PrEP adherence.
PRE-EXPOUSRE PROPHYLAXIS AMONG 
FEMALE SEX WORKERS: BARRIERS AND 
STRATEGIES TO INCREASE ADHERENCE
All of the evidence above highlights the complexity of PrEP 
adherence among FSWs. Proactive educational intervention, 
lifestyle modifications, concerns for convenience and FSWs 
preferences, and finally, alleviation of economic burden have 
been shown to play an important role in PrEP adherence and 
subsequent HIV control outcomes. Although multiple clinical 
trials have indicated that FSWs are interested in using PrEPs,38,45,46 
this willingness is not always translated into actual PrEP use 
or adherence.
Social values and stigma are difficult to address and modify, 
and long-term educational efforts to change notions, judg-
ment, and stigmas in local communities towards PrEP use are 
needed. Church-based efforts to promote screening and mod-
ify health behaviors have been successful, and thus, working 
in partnership with religious communities may potentially 
help shift attitudes towards HIV/AIDS and PrEP. Indeed, faith 
leaders have been shown to hold the potential to play a pivot-
al role in HIV de-stigmatization and in increasing collective 
acceptance of efforts to control HIV, such as PrEP usage, in the 
community.47,48
Brothel leadership and their faciliatory role in condom use 
has been shown to limit HIV exposure among FSWs and their 
clients.49 Similarly, cooperation from brothel owners may also 
be relevant to promoting PrEP use. With support, it is likely that 
FSWs will be more inclined to adhere to PrEP intervention.
Educational initiatives at the individual and community 
level should be administered regularly to promote adherence. 
These efforts should be directed towards healthcare workers 
in local communities, FSWs, and different stakeholders, in-
cluding religious figures and brothel owners. Multiple studies 
have shown that innovative educational training strategies re-
sult in better HIV risk assessment and can overcome many 
barriers to PrEP prescription.50,51 
Motivational interviews have proven to be effective in pro-
moting PrEP use among men having sex with men.52,53 For FSWs, 
motivational interviewing may facilitate assessing the pros 
and cons of taking PrEP and explaining them in lay terms to 
FSWs, allowing FSWs to understand the very low risk and great 
benefits of such a prophylactic approach. Discussions and/or 
consultations should be centered and focused on FSWs, em-
powering them to choose PrEP and to adhere to the prescribed 
regimen. To reinforce PrEP adherence, healthcare workers 
should consider FSW preferences, needs, and context. Indeed, 
better HIV and PrEP knowledge and education have been 
shown to lead to protection seeking behavior among FSWs, 
encouraging them to better adhere to the PrEP regimen.15,35
One special sub-group of FSWs worth mentioning is female 
workers of a younger age. Special attention should be given to 
younger FSWs as previous studies have expressed concerns of 
lower adherence in this population. Evidence from wide scaling 
of the treatment points out that younger people find it more chal-
lenging to adhere to treatment than older individuals,54 and 
many may need increased adherence encourengment tailored 
to their age group and lifestyle.55 In a phase III trial on dapiv-
irine vaginal ring,56 adherence was lowest in the younger age 
group: women aged 18–21 years had lower adherence than 
those aged over 21 years.54 This subsequently led to a major de-
crease in the efficacy of the intervention.56,57
Almost all oral PrEP prescriptions consist of daily pills, which 
is an important hurdle and barrier to adherence. Neverthe-
less, the inconvenience of daily pills might be overcome with 
research on next-generation PrEP products. In the meantime, 
there is a need to consider existing vaginal practices to ensure 
the development of safe and effective vaginal PrEP products.58,59 
Implementation of various PrEP product formulations, includ-
ing behaviorally-congruent vaginal gels and douches, have 
been shown to enhance future PrEP uptake and adherence and 
to ultimately reduce the burden of HIV among FSWs.59 How-
ever, reports have warned of a potential interaction or dilution 
of PrEP effectiveness with concomitant use of vaginal washing 
or lubrication with vaginal gel- or douche-based PrEP prod-
ucts.60 Some options that have been proposed to avert the dai-
ly usage of PrEP is an intermittent protocol. Notwithstanding, 
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major concerns have been raised regarding the efficiency of in-
termittent dosage. A mathematical model in fact proved that 
the highest HIV protection is directly correlated with the exact 
number of PrEP doses per week and is not dependent on the 
dosage interval.61 Furthermore, intermittent PrEP dosing has 
not been universally adopted as a safe alternative to daily use, 
because references could not agree on a single definition nor 
frequency for intermittent protocols.62 Newer and promising 
PrEP formulations, including weekly controlled slow-release 
dosages and long-acting oral pills, may provide a potential so-
lution to poor adherence with currently available regimens.63 
In the last two decades, major international and local gov-
ernmental/non-governmental agencies have worked relent-
lessly to limit HIV through preventative efforts.64 Controlling 
HIV has proven to improve economic growth and productivity, 
prosperity, and quality of life indices, especially in middle- and 
low-income countries.65 Focusing on high-risk groups for HIV 
prevention, such as FSWs, has been reported to be cost-effec-
tive:66 targeted intervention for FSWs has proven to result in a 
47% reduction in HIV prevalence and 36% reduction in cumu-
lative HIV cases.67 Interestingly, among the FSW population 
specifically, PrEP has been shown to have limited cost-effec-
tiveness in HIV prevention.68 This is probably due to the eco-
nomic and financial vulnerabilities that FSW populations face, 
which can make additional PrEP costs a major challenge to 
adherence. In order to overcome the economic burden of PrEP, 
advocates should fight to have PrEP covered by health insur-
ance.39 
Facilitators of and barriers to efficient PrEP adherence are 
summarized in Table 2. Some high-yield facilitators for PrEP 
adherence include educational and motivational interven-
tions, social support, and making sure healthcare is guaran-
teed. All these interventions occur at the individual, social, 
and structural level, respectively.
A summary of barriers to PrEP adherence among FSWs and 
potential ways to overcome them are presented in Fig. 2. Ad-
herence to PrEP faces multiple barriers at the individual, social, 
structural, and economic level. Multiple stakeholders must co-
ordinate and act in synergy to help overcome these barriers.
Other interventions have also been described in the litera-
ture among other high-risk groups for HIV to increase PrEP 
adherence. The CDC, in 2014, included in their guideline al-
gorithms regular PrEP adherence counseling actions for ad-
herence optimization.50,51 A weekly counseling session deliv-
Table 2. Facilitators of and Barriers to Efficient PrEP Adherence Protocols at the Individual, Social, and Structural Level among Female Sex Work-
ers62-65
High-yield facilitators of PrEP usage adherence Major barriers to PrEP usage and adherence
Individual level PrEP education and motivation to maintain good health Poor knowledge of PrEP, doubts about its effectiveness, fear of side effects, 
low perception of HIV risk, and the need to adhere to multiple medications
Social level Partner, peer, and family support Anticipated stigma from peers, partners, and family members related to sexual 
orientation, PrEP, and/or HIV status
Structural level Presence of and good out-reach from healthcare workers 
and establishments, financial support, and patient privacy
Concerns regarding attitudes of healthcare providers, quality assurance, data 
protection, and cost
PrEP, pre-exposure prophylaxis; HIV, human immunodeficiency virus.
Social values and stigma 
Lack of enough education on PrEP
Different lifestyles
Inconvenience 
Economic burden
A long-term educational effort to change notions of local community
Carefully designed education done frequently 
Lifestyle modification
Research on next-generation PrEP products
An effective integration of PrEP into existing services such as social safety net, 
insurance and others
Fig. 2. Summary of barriers to PrEP adherence among female sex workers and ways to overcome them. PrEP, pre-exposure prophylaxis.
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ered by a dedicated nurse has been found to result in 84% 
adherence to the PrEP regimen at 6 months after the interven-
tion for MSM.51 Kar, et al.69 coined the acronym EMPOWER as 
an approach to improve adherence, consisting of the following 
actions and interventions: “Education/leadership develop-
ment, Media/Advocacy, Public education/Participation, Orga-
nizing associations/Unions, Work training/micro-enterprise, 
Enabling services/Assistance, and Rights protection/Promo-
tion.”69 Even though this approach is comprehensive, its realis-
tic application among FSWs can be extremely challenging and 
unrealistic in some instances.
CONCLUSION
FSWs are a vulnerable population and frequently subjected to 
violence, stigma, marginalization, economic, and social hard-
ship. All of these factors pose barriers to sexual reproductive 
health and HIV preventative interventions. Research has re-
peatedly shown that low PrEP adherence accounts for the lack 
of efficiency with this intervention in protecting against HIV. 
Therefore, PrEP adherence strategies should be developed and 
designed as a holistic approach, acknowledging the contextu-
al factors of FSWs. Targeted interventions taking into account 
socio-cultural, economic, and individual preferences have the 
potential to assure the highest adherence level. To achieve HIV/
sexually transmitted infection PrEP intervention goals, a model 
among multiple stakeholders should intervene at the structural, 
environmental, community, and personal/individual level in or-
der to achieve the maximum protection and to ensure FSW 
wellbeing. Combined interventions that are designed to build 
self-efficacy, empowerment, and social cohesion with evidence-
based individualized adherence support are likely to be most 
effective (Table 2).70-72 Designing tailored approaches to PrEP 
delivery and adherence support, based on each individual par-
ticipant’s needs and preferences,14 is necessary for future inter-
ventions. A conceptual framework73 that can be used to locate 
where the adherence interventions lie in the greater picture of 
HIV/AIDS intervention and its impact is needed.
Ultimately, more research should be conducted in real-world 
settings to help design and implement creative and original 
interventions with the purpose of maximizing HIV/AIDS pro-
tection among FSWs. Adopting such targeted and population-
specific approaches will ultimately contribute to efforts aim-
ing to control the HIV/AIDS epidemic.
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